Innoviva

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. 

Type
Public
HQ
South San Francisco, US
Size (employees)
14 (est)+8%
Website
inva.com
Innoviva is headquartered in South San Francisco, US

Innoviva Office Locations

Innoviva has an office in South San Francisco
South San Francisco, US (HQ)
951 Gateway Blvd

Innoviva Metrics

Innoviva Financial Metrics

Revenue (2016)

$133.6 m

Revenue growth (2015-16), %

148%

Net income (2016)

$59.5 m

Market capitalization (28-Apr-2017)

$1.3 b

Closing share price (28-Apr-2017)

$12.6

Cash (31-Dec-2016)

$118 m
Innoviva's current market capitalization is $1.3 b.
Innoviva's revenue was reported to be $133.6 m in FY, 2016 which is a 148% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$4.8 m$8.4 m$53.9 m$133.6 m

Revenue growth, %

77%540%148%

Operating expense total

$173.6 m$42.4 m$22.4 m$24.6 m

EBIT

($168.9 m)($33.9 m)$31.6 m$109 m

EBIT margin, %

(3549%)(402%)59%82%

Interest expense

$9.3 m$36.9 m$51.8 m$52.4 m

Interest income

$778 k$563 k$343 k$582 k

Pre tax profit

($18.8 m)$59.5 m

Income tax expense

Net Income

($170.7 m)($168.5 m)($18.8 m)$59.5 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$143.5 m$96.8 m$159.2 m$118 m

Accounts Receivable

Inventories

$10.4 m$814 k$766 k

Current Assets

$483.2 m$252.2 m$214.3 m$198 m

PP&E

$10.2 m$324 k$221 k$368 k

Total Assets

$681.3 m$521.7 m$424.1 m$379 m

Accounts Payable

$7.6 m$818 k$128 k

Current Liabilities

$84.4 m$13.8 m$13.5 m$20 m

Additional Paid-in Capital

$1.8 b$1.5 b$1.4 b$1.3 b

Retained Earnings

($1.5 b)($1.7 b)($1.7 b)($1.6 b)

Total Equity

$299.1 m($223.3 m)($342.6 m)($353 m)

Financial Leverage

2.3 x-2.3 x-1.2 x-1.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($170.7 m)($168.5 m)($18.8 m)$59.5 m

Depreciation and Amortization

$8.2 m$12.2 m$13.9 m$14 m

Accounts Receivable

Inventories

($3.1 m)($1.9 m)

Accounts Payable

$1.6 m($7.7 m)$818 k($690 k)

Cash From Operating Activities

($129.6 m)($130.7 m)$10.1 m$61 m

Purchases of PP&E

($2.7 m)($689 k)($7 k)($278 k)

Cash From Investing Activities

($219.6 m)($65.1 m)$159.2 m($4.6 m)

Cash From Financing Activities

$397.8 m$149.1 m($106.9 m)($97.6 m)

Interest Paid

$8 m$9.2 m$25.9 m$48.8 m

Innoviva Operating Metrics

FY, 2016

Patents Issued

33

Patents Granted

97

Innoviva Market Value History

Innoviva News

Innoviva Company Life

You may also be interested in